Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 5:15 p.m. PT.
紐約，2024年12月23日（GLOBE NEWSWIRE）——專注於開發和商業化用於治療癌症的新型放射免疫療法和基於抗體的治療產品的商業化階段生物製藥公司Y-mAbs Therapeutics, Inc.（「公司」 或 「Y-mABS」）（納斯達克股票代碼：YMAB）今天宣佈，總裁兼首席執行官邁克爾·羅西將出席第 43 屆摩根大通醫療保健年度會議將於太平洋時間2025年1月15日星期三下午 5:15 在加利福尼亞州舊金山舉行
A live webcast will be available under the Events section of the Company's investor relations website at ir.ymabs.com. The webcast will be archived and available for replay for 30 days after the event.
將在公司投資者關係網站ir.ymabs.com的 「活動」 部分下進行網絡直播。網絡直播將在活動結束後的30天內存檔並可供重播。
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company's technologies include its investigational Self-Assembly DisAssembly ("SADA") Pretargeted Radioimmunotherapy Platform ("PRIT") and bispecific antibodies generated using the Y-BiClone platform. The Company's broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
關於 Y-mabs
Y-mabs是一家處於商業階段的生物製藥公司，專注於新型放射免疫療法和基於抗體的治療性癌症產品的開發和商業化。該公司的技術包括其研究中的自組裝拆卸（「SADA」）預靶向放射免疫治療平台（「PRIT」）和使用Y-biclone平台生成的雙特異性抗體。該公司廣泛而先進的產品線包括抗GD2療法DANYELZA（naxitamab-gqgk），這是第一款經美國食品藥品管理局批准的針對骨髓或骨髓中復發或難治性高風險神經母細胞瘤患者的治療方法，該療法對先前療法有部分反應、輕微反應或病情穩定。
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond.Words such as ''anticipate,'' ''believe,'' "contemplate," ''continue,'' ''could,'' ''estimate,'' ''expect,'' "hope," ''intend,'' ''may,'' ''might,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''should,'' ''target,'' "will," ''would',' "guidance," "goal," "objective," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company's business is subject to risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and the Company's Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
前瞻性陳述
根據1933年《證券法》第27A條和1934年《證券交易法》第21E條的定義，本新聞稿中有關未來預期、計劃和前景的陳述，以及有關非歷史事實事項的任何其他陳述，可能構成 「前瞻性陳述」。此類陳述包括但不限於有關我們商業模式的陳述，包括2024年及以後的財務前景。諸如 「預測」、「相信」、「考慮」、「繼續」、「可能」、「估計」、「預期」、「希望」、「打算」、「可能」、「計劃」、「潛力」、「預測」、「項目」、「應該」、「目標」、「目標」、” 「將」、「將來」、「指導」、「目標」、「目標」 和類似的表述旨在識別前瞻性陳述，儘管並非所有前瞻性陳述都包含這些識別詞。公司的業務受到影響公司的風險和不確定性的影響，包括公司截至2023年12月31日財年的10-k表年度報告、截至2024年3月31日和2024年9月30日的公司10-Q表季度報告以及公司未來申報和報告中的 「風險因素」 部分中描述的風險和不確定性。本新聞稿中包含的任何前瞻性陳述僅代表截至本新聞稿發佈之日，公司沒有義務更新任何前瞻性陳述，無論是由於新信息、未來事件還是其他原因。
SADA, SADA PRIT, DANYELZA and Y-mAbs are registered trademarks of Y-mAbs Therapeutics, Inc.
SADA、SADA PRiT、DANYELZA 和 Y-maBS 是 Y-mAbs Therapeutics, Inc. 的註冊商標。
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
[email protected]
投資者聯繫方式：
考特尼·杜根
副總裁，投資者關係主管
[電子郵件保護]
Source: Y-mAbs Therapeutics, Inc.
資料來源：Y-mAbs Therapeutics, Inc.
譯文內容由第三人軟體翻譯。
